Clinical Trial Update: Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy of the idarubicin, cytarabine, and cyclophosphamide (IAC) regimen in relapsed/refractory acute myeloid leukemia, and the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED